Literature DB >> 18556649

Artificial envelopment of nonenveloped viruses: enhancing adenovirus tumor targeting in vivo.

Ravi Singh1, Bowen Tian, Kostas Kostarelos.   

Abstract

Recombinant adenovirus (Ad) is a powerful tool in gene therapy. However, the ability to deliver Ad by systemic administration is limited due to rapid clearance from blood circulation, transfection of nontarget tissues, toxicity, and immunogenicity. To address these limitations, we developed an artificially enveloped Ad vector prepared by self-assembly of lipid bilayers around the Ad capsid. The physicochemical and structural features of the enveloped Ad vector can be altered according to the type of lipid used without the need for genetic modification or conjugation chemistry. Here we engineered 4 different types of artificially enveloped Ad using cationic, neutral, fusogenic, and PEGylated lipids to form the envelopes and obtained extended blood circulation times following i.v. administration and reduced vector immunogenicity. Moreover, the PEGylated lipid-enveloped Ad was capable of specifically delivering genes via the systemic circulation to solid tumors subcutaneously implanted in the absence of high levels of gene transfer to the liver and spleen. This provides the basis for the development of a novel vector platform for systemic delivery of Ad to disseminated targets. Furthermore, the artificial envelopment of Ad presented herein is an illustration of a general strategy to modulate the biological function of nonenveloped viruses and may have implications broader than gene therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18556649     DOI: 10.1096/fj.08-103275

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  9 in total

Review 1.  Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials.

Authors:  Jaesung Kim; Pyung-Hwan Kim; Sung Wan Kim; Chae-Ok Yun
Journal:  Biomaterials       Date:  2011-12-03       Impact factor: 12.479

2.  The transduction of Coxsackie and Adenovirus Receptor-negative cells and protection against neutralizing antibodies by HPMA-co-oligolysine copolymer-coated adenovirus.

Authors:  Chung-Huei K Wang; Leslie W Chan; Russell N Johnson; David S H Chu; Julie Shi; Joan G Schellinger; André Lieber; Suzie H Pun
Journal:  Biomaterials       Date:  2011-09-28       Impact factor: 12.479

Review 3.  Biomimetic nanoparticles: preparation, characterization and biomedical applications.

Authors:  Ana Maria Carmona-Ribeiro
Journal:  Int J Nanomedicine       Date:  2010-04-07

4.  Protection of adenovirus from neutralizing antibody by cationic PEG derivative ionically linked to adenovirus.

Authors:  Qin Zeng; Jianfeng Han; Dong Zhao; Tao Gong; Zhirong Zhang; Xun Sun
Journal:  Int J Nanomedicine       Date:  2012-02-27

5.  Development of dual-activity vectors by co-envelopment of adenovirus and SiRNA in artificial lipid bilayers.

Authors:  Açelya Yilmazer; Bowen Tian; Kostas Kostarelos
Journal:  PLoS One       Date:  2014-12-12       Impact factor: 3.240

6.  Design of expert guided investigation of native L-asparaginase encapsulated long-acting cross-linker-free poly (lactic-co-glycolic) acid nanoformulation in an Ehrlich ascites tumor model.

Authors:  Manvi Singh; Nazia Hassan; Devina Verma; Pragya Thakur; Bibhu Prasad Panda; Amulya Kumar Panda; Rakesh Kumar Sharma; Aamir Mirza; Sheikh Mansoor; Salman H Alrokayan; Haseeb A Khan; Parvaiz Ahmad; Zeenat Iqbal
Journal:  Saudi Pharm J       Date:  2020-05-06       Impact factor: 4.330

Review 7.  The evolution of adenoviral vectors through genetic and chemical surface modifications.

Authors:  Cristian Capasso; Mariangela Garofalo; Mari Hirvinen; Vincenzo Cerullo
Journal:  Viruses       Date:  2014-02-17       Impact factor: 5.048

8.  The targeted transduction of MMP-overexpressing tumor cells by ACPP-HPMA copolymer-coated adenovirus conjugates.

Authors:  Shuhua Li; Juanzhi Chen; Huiyong Xu; Jie Long; Xiaobin Xie; Yajie Zhang
Journal:  PLoS One       Date:  2014-07-07       Impact factor: 3.240

9.  A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines.

Authors:  Daniela Peruzzi; Sridhar Dharmapuri; Agostino Cirillo; Bruno Ercole Bruni; Alfredo Nicosia; Riccardo Cortese; Stefano Colloca; Gennaro Ciliberto; Nicola La Monica; Luigi Aurisicchio
Journal:  Vaccine       Date:  2009-01-20       Impact factor: 3.641

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.